You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Dow
Medtronic
McKesson
McKinsey

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

POSITIVE SKIN TEST CONTROL - HISTAMINE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for POSITIVE SKIN TEST CONTROL - HISTAMINE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
KeraNetics, LLCN/A
State University of New York - Downstate Medical CenterPhase 2
Universidade Federal de PernambucoPhase 3

See all POSITIVE SKIN TEST CONTROL - HISTAMINE clinical trials

Recent Litigation for POSITIVE SKIN TEST CONTROL - HISTAMINE

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ackerman v. Given2019-10-18
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
Bayer HealthCare Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership2018-02-15

See all POSITIVE SKIN TEST CONTROL - HISTAMINE litigation

PTAB Litigation
PetitionerDate
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC2020-01-31
2018-05-25
2017-02-02

See all POSITIVE SKIN TEST CONTROL - HISTAMINE litigation

Patent Text Search: US Patents for POSITIVE SKIN TEST CONTROL - HISTAMINE

These patents were identified by searching patent claims

Supplementary Protection Certificates for POSITIVE SKIN TEST CONTROL - HISTAMINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
7/2008 Austria   Start Trial PRODUCT NAME: RUPATADIN UND DESSEN SALZE UND SOLVATE, EINSCHLIESSLICH RUPATADIN-FUMARATE; NAT. REGISTRATION NO/DATE: 1-27273 20071115; FIRST REGISTRATION: ES 64.053 20010704
13C0067 France   Start Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
06C0006 France   Start Trial PRODUCT NAME: OMALIZUMAB ET SES FORMES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/05/319/001 DU 20051025; REGISTRATION NO/DATE AT EEC: E/1/05/319/001 DU 20051025
122008000029 Germany   Start Trial PRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
CA 2013 00023 Denmark   Start Trial
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Dow
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.